Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population

Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured... Rheumatol Ther (2018) 5:355–369 https://doi.org/10.1007/s40744-018-0114-6 ORIGINAL RESEARCH Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population . . . David M. Kern Lawrence Chang Kalyani Sonawane . . . Cynthia J. Larmore Natalie N. Boytsov Ralph A. Quimbo . . . Joseph Singer John T. Hinton Sze-jung Wu Andre B. Araujo Received: February 27, 2018 / Published online: May 30, 2018 The Author(s) 2018 DMARD treatment, including conventional ABSTRACT synthetic DMARDs (csDMARD), tumor necrosis factor inhibitors (TNFi), non-TNFi, and Janus Introduction: To describe treatment patterns in kinase inhibitors (JAKi), were captured during newly diagnosed rheumatoid arthritis (RA) follow-up. patients in a large, nationally representative Results: Of the 63,101 RA patients identified, managed-care database. 73% were female; mean age was 57 years. Dur- Methods: Newly diagnosed RA patients were ing an average of 3.5 ± 2.1 years of follow-up, identified from 07/01/2006–08/31/2014. 45% of patients never received a DMARD, 52% Patients had C 1 RA diagnosis by a rheumatol- received a csDMARD (94 ± 298 mean ± SD days ogist, or C 2 non-rheumatologist RA diagnoses from index), 16% a TNFi (315 ± 448 days), 4% a C 30 days apart, or RA diagnosis followed by http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Rheumatology and Therapy Springer Journals

Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population

Loading next page...
 
/lp/springer_journal/treatment-patterns-of-newly-diagnosed-rheumatoid-arthritis-patients-7SXUTedS7E

References (60)

Publisher
Springer Journals
Copyright
Copyright © 2018 by The Author(s)
Subject
Medicine & Public Health; Rheumatology; Orthopedics; General Practice / Family Medicine; Internal Medicine; Quality of Life Research
ISSN
2198-6576
eISSN
2198-6584
DOI
10.1007/s40744-018-0114-6
Publisher site
See Article on Publisher Site

Abstract

Rheumatol Ther (2018) 5:355–369 https://doi.org/10.1007/s40744-018-0114-6 ORIGINAL RESEARCH Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population . . . David M. Kern Lawrence Chang Kalyani Sonawane . . . Cynthia J. Larmore Natalie N. Boytsov Ralph A. Quimbo . . . Joseph Singer John T. Hinton Sze-jung Wu Andre B. Araujo Received: February 27, 2018 / Published online: May 30, 2018 The Author(s) 2018 DMARD treatment, including conventional ABSTRACT synthetic DMARDs (csDMARD), tumor necrosis factor inhibitors (TNFi), non-TNFi, and Janus Introduction: To describe treatment patterns in kinase inhibitors (JAKi), were captured during newly diagnosed rheumatoid arthritis (RA) follow-up. patients in a large, nationally representative Results: Of the 63,101 RA patients identified, managed-care database. 73% were female; mean age was 57 years. Dur- Methods: Newly diagnosed RA patients were ing an average of 3.5 ± 2.1 years of follow-up, identified from 07/01/2006–08/31/2014. 45% of patients never received a DMARD, 52% Patients had C 1 RA diagnosis by a rheumatol- received a csDMARD (94 ± 298 mean ± SD days ogist, or C 2 non-rheumatologist RA diagnoses from index), 16% a TNFi (315 ± 448 days), 4% a C 30 days apart, or RA diagnosis followed by

Journal

Rheumatology and TherapySpringer Journals

Published: May 30, 2018

There are no references for this article.